...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer Growth and Metastasis >Impact of Transfusion on Cancer Growth and Outcome
【24h】

Impact of Transfusion on Cancer Growth and Outcome

机译：输血对癌症生长和结果的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

For many years, transfusion of allogeneic red blood cells, platelet concentrates, and plasma units has been part of the standard therapeutic arsenal used along the surgical and nonsurgical treatment of patients with malignancies. Although the benefits of these blood products are not a matter of debate in specific pathological conditions associated with life-threatening low blood cell counts or bleeding, increasing clinical evidence is nevertheless suggesting that deliberate transfusion of these blood components may actually lead to negative clinical outcomes by affecting patient's immune defense, stimulating tumor growth, tethering, and dissemination. Rigorous preclinical and clinical studies are needed to dimension the clinical relevance, benefits, and risks of transfusion of blood components in cancer patients and understand the amplitude of problems. There is also a need to consider validating preparation methods of blood components for so far ignored biological markers, such as microparticles and biological response modifiers. Meanwhile, blood component transfusions should be regarded as a personalized medicine, taking into careful consideration the status and specificities of the patient, rather than as a routine hospital procedure.
机译：多年来，异基因红细胞，血小板浓缩液和血浆单位的输血已成为恶性肿瘤患者手术和非手术治疗中使用的标准治疗武库的一部分。尽管在与威胁生命的低血球计数或出血相关的特定病理学条件下，这些血液制品的益处并不成问题，但越来越多的临床证据表明，有意输注这些血液成分实际上可能导致不良的临床结果。影响患者的免疫防御能力，刺激肿瘤生长，系留和扩散。需要进行严格的临床前和临床研究来确定癌症患者输血的临床相关性，益处和输血风险，并了解问题的严重性。还需要考虑对迄今为止被忽略的生物标记物，例如微粒和生物反应调节剂，验证血液成分的制备方法。同时，应仔细考虑患者的状况和特异性，将血液成分输注视为一种个性化药物，而不是常规的医院程序。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号